Combination of racotumomab immunotherapy with programmed death-1 blockade in a preclinical model of non-small cell lung cancer.

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death. Treatment options include surgery, chemotherapy, radiotherapy, and immunotherapy, such as anti-programmed death-1 (PD-1) monoclonal antibody (mAb) pembrolizumab. Combining anti-PD-1 therapy with other active immunotherapies is an interesting option for improving patient outcomes. Racotumomab, an anti-idiotype mAb used as switch maintenance therapy in advanced NSCLC, enhances immune responses against N-glycolylneuraminic acid (NeuGc)-containing neoantigens. This study aims to assess the antitumor effects of an anti-murine PD-1 mAb in combination with racotumomab immunotherapy in a preclinical mouse model of NSCLC.

Methods

In the present study, we assessed the antitumor effects of an anti

SUBMITTER: Segatori VI 

PROVIDER: S-EPMC12541832 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature